Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy

Blood (2023) 142 (Supplement 1): 3504.

https://doi.org/10.1182/blood-2023-190388

Published: 2023

Journal Articles

A Phase 1 Study of NKX101, a Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Therapy, with Fludarabine and Cytarabine in Patients with Acute Myeloid Leukemia

Craig S Sauter, Gautam Borthakur, Luke Mountjoy, Marcello Rotta, Hongtao Liu, Hemant S. Murthy, Ming Lin, James Trager, Cornell Chang, Nishi Kothari, David Shook, Carlos Bachier

Blood (2023) 142 (Supplement 1): 2097.

https://doi.org/10.1182/blood-2023-173582

Published: 2023

Journal Articles

Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 3479.

https://doi.org/10.1182/blood-2023-182430

Published: 2023

Journal Articles

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

Blood (2023) 141 (20): 2470–2482.

https://doi.org/10.1182/blood.2022018598

Published: 2023

Includes: Supplemental data

Journal Articles

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Blood (2022) 140 (Supplement 1): 10303–10306.

https://doi.org/10.1182/blood-2022-166432

Published: 2022

Journal Articles

Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Yuliya Linhares, Cesar Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris, Daanish Hoda, Juan Carlos Varela, Courtney Bellomo, Scott Cross, James Essell, Suzanne Fanning, Howard Terebelo, Habte Yimer, Jay Courtright, Jeff P. Sharman, Min Vedal, Connor Mailley, Ricardo Espinola, Bassam Mattar

Blood (2022) 140 (Supplement 1): 10416–10418.

https://doi.org/10.1182/blood-2022-159595

Published: 2022

Journal Articles

Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

Blood (2022) 140 (Supplement 1): 654–656.

https://doi.org/10.1182/blood-2022-165654

Published: 2022

Journal Articles

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Blood (2021) 138 (22): 2278–2289.

https://doi.org/10.1182/blood.2021012021

Published: 2021

Includes: Supplemental data

Journal Articles

A Phase II Single Arm Study of Nivolumab As Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma at Risk of Relapse or Progression

Carlos Bachier, Henning Schade, Behyar Zoghi, Aravind Ramakrishnan, Nirav N. Shah

Blood (2021) 138 (Supplement 1): 2455.

https://doi.org/10.1182/blood-2021-148139

Published: 2021

Journal Articles

Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

John E. Godwin, Bassam Mattar, Michael Maris, Carlos Bachier, Don Stevens, Daanish Hoda, Juan C. Varela, Mohamad Cherry, Suzanne Fanning, James Essell, Habte Yimer, Jay Courtright, Jeff P. Sharman, Ricardo Espinola, Connor Mailley, Ariel Avilion, Ken Ogasawara, San-San Ou, Paul Shaughnessy

Blood (2021) 138 (Supplement 1): 1762.

https://doi.org/10.1182/blood-2021-148792

Published: 2021

Journal Articles

Budget Impact Analysis of Belumosudil for Chronic Graft-Versus-Host Disease Treatment in the United States

Carlos Bachier, Jeffrey Rolf Skaar, Sumudu Dehipawala, Benjamin Miao, Jonathan Ieyoub, Haya Taitel

Blood (2021) 138 (Supplement 1): 1903.

https://doi.org/10.1182/blood-2021-146839

Published: 2021

Journal Articles

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Minoo Battiwalla, MD, Carlos Bachier, MD, Vikas Bhushan, MD, Michael J. Eckrich, MD MPH, Alireza Eghtedar, MD, Haydar Frangoul, MD, Suman Kambhampati, MD, Shahbaz Malik, MD, Peter A. McSweeney, MD, Jeremy Pantin, MBBS, Aravind Ramakrishnan, MD, Hana Safah, MD, Paul J Shaughnessy, MD, Betsy Blunk, BSN, RN, BMTCN, Tonya Cox, BSN, RN, Rocky Billups, MS, Charles F. Lemaistre, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-139121

Published: 2020

Journal Articles

Costs and Adverse Events Associated with Ibrutinib or Ruxolitinib in Chronic Graft-Versus-Host Disease

Carlos Bachier, MD, David Eiznhamer, PhD, Andrew Milgroom, MS, Mara Lenco, MS, Nayan Patel, MS, Jeffrey Rolf Skaar, PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137756

Published: 2020

Journal Articles

Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study

John E. Godwin, MD, Cesar O. Freytes, MD, Michael Maris, MD, Don A. Stevens, MD, Daanish Hoda, MD, Bassam Mattar, MD, Juan C. Varela, MDPhD, Mohamad Cherry, MDMS, James Essell, MD, Jay Courtright, MD, Suzanne R. Fanning, DO, Habte A. Yimer, MD, Nikolaus S. Trede, MD PhD, Marina Youssef, PharmD, James Lymp, PhD, Carlos Bachier, MD

Blood (2020) 136 (Supplement 1): 50–52.

https://doi.org/10.1182/blood-2020-136640

Published: 2020

Journal Articles

A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)

Carlos Bachier, MD, Gautam Borthakur, MD, Chitra Hosing, MD, William Blum, MD, Marcello Rotta, MD, Paulius Ojeras, Brian Barnett, MD, Kanya Rajangam, MD PhD, Navneet S. Majhail, MD MS, Sarah Nikiforow, MD PhD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-134625

Published: 2020

Journal Articles

Outcomes of Autologous Transplants for Patients with Multiple Myeloma and Concurrent Multiple Plasmacytomas

Seema Naik, MD, Paul J. Shaughnessy, MD, Behyar Zoghi, MDPhD, Jose C Cruz, MD, Carlos Bachier, MD

Blood (2015) 126 (23): 1973.

https://doi.org/10.1182/blood.V126.23.1973.1973

Published: 2015

Journal Articles

The VIP (Very Immunocompromised Patient) Protocol: Improved Access To Care and Time To Antibiotics

Paul J. Shaughnessy, MD, Ann Kelley, RN, Roberta Tremper, RN, Jonathan Tinker, Carlos Bachier, MD, Joseph Holahan, MD, Roger M. Lyons, MD, Charles F. LeMaistre, MD

Blood (2013) 122 (21): 2978.

https://doi.org/10.1182/blood.V122.21.2978.2978

Published: 2013

Journal Articles

High Correlation of Pre-Apheresis Peripheral Blood CD34+ Cell Counts with Final Apheresis Product CD34+ Cell Count by Using a More Accurate Determination of Patient Blood Volume

Brandon Parker, James Hastings, Jill Folkert, RN, Gayla Nagy, RN, Carlos Bachier, MD, Charles F. LeMaistre, MD, Paul Shaughnessy, MD

Blood (2011) 118 (21): 2996.

https://doi.org/10.1182/blood.V118.21.2996.2996

Published: 2011

Journal Articles

Mismatches in Ethnicity Between Donor and Recipient Affects Overall Survival In Umbilical Cord Blood Transplantation,

Patali Shikhi Cheruku, Veronica H. Jude, MD, Renee M Madden, MD, Charles F. LeMaistre, MD, Ka Wah Chan, MD, MBBS, Paul Shaughnessy, MD, Carlos Bachier, MD

Blood (2011) 118 (21): 4159.

https://doi.org/10.1182/blood.V118.21.4159.4159

Published: 2011

Journal Articles

Prophylaxis of Acute Gvhd Using Stromal Cell Therapy: Preliminary Results After Administration of Single or Multiple Doses of Multistem® in a Phase I Trial

Richard T. Maziarz, MD, Timothy deVos, M.D., Carlos Bachier, MD, Steven C. Goldstein, MD, Jose F. Leis, MD, PhD, Robert Perry, B.S., Robert Deans, PhD, Wouter J Van't Hof, PhD, Hillard M. Lazarus, MD

Blood (2011) 118 (21): 1987.

https://doi.org/10.1182/blood.V118.21.1987.1987

Published: 2011

NARROW

Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy

A Phase 1 Study of NKX101, a Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Therapy, with Fludarabine and Cytarabine in Patients with Acute Myeloid Leukemia

Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

A Phase II Single Arm Study of Nivolumab As Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma at Risk of Relapse or Progression

Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

Budget Impact Analysis of Belumosudil for Chronic Graft-Versus-Host Disease Treatment in the United States

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Costs and Adverse Events Associated with Ibrutinib or Ruxolitinib in Chronic Graft-Versus-Host Disease

Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study

A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)

Outcomes of Autologous Transplants for Patients with Multiple Myeloma and Concurrent Multiple Plasmacytomas

The VIP (Very Immunocompromised Patient) Protocol: Improved Access To Care and Time To Antibiotics

High Correlation of Pre-Apheresis Peripheral Blood CD34+ Cell Counts with Final Apheresis Product CD34+ Cell Count by Using a More Accurate Determination of Patient Blood Volume

Mismatches in Ethnicity Between Donor and Recipient Affects Overall Survival In Umbilical Cord Blood Transplantation,

Prophylaxis of Acute Gvhd Using Stromal Cell Therapy: Preliminary Results After Administration of Single or Multiple Doses of Multistem® in a Phase I Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only